AHA today voiced support for a number of proposed changes to the Medicare Advantage and Part D programs aimed at increasing plan negotiating power to lower drug prices, but emphasized “the importance of strong patient protections to ensure continuity of care, the application of medical necessity, an expedited appeals process, and required review and approval of MA step therapy plans by respective Pharmacy and Therapeutic Committees.” The proposed rule would allow Part D plans to exclude certain drugs from their formularies with the objective of negotiating lower drug prices; codify a recent change in policy that allowed MA plans to require beneficiaries to try cost-effective Part B drug therapies before progressing to more expensive options; require Part D plans to implement by 2020 electronic tools to inform prescribers of beneficiary-specific drug coverage and lower-cost therapeutic alternatives available to the enrollee; and require Part D plans to include information about changes in drug prices and lower-cost therapeutic alternatives in their explanation of benefits.

Related News Articles

Headline
The AHA Sept. 3 released a study conducted by KNG Health Consulting that found Medicare patients who receive care in a hospital outpatient department are more…
Headline
The AHA Aug. 28 expressed support for the Preserving Patient Access to Accountable Care Act in comments to House and Senate sponsors of the bill. The…
Headline
The AHA’s Society for Health Care Strategy & Market Development Aug. 21 announced Donna Teach, chief marketing and communications officer for Nationwide…
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
A JAMA study published Aug. 18 found that plan design changes by Medicare Part D insurers, particularly for Medicare Advantage plans, following passage of the…
Perspective
Public
The job description for the ideal health care leader in coming years might read something like this:Wanted: Bold, compassionate innovator who unites clinical…